Imaplix

Apremilast, the active ingredient in Imaplix, is a phosphodiesterase 4 (PDE4) inhibitor presented as an oral tablet for oral use. It is prescribed for adult patients with moderate to severe plaque psoriasis and for those with active psoriatic arthritis, providing a systemic treatment option without injection.

GNH USA supplies Imaplix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for bulk and individual orders.

Imaplix (apremilast) is used to manage inflammatory skin and joint conditions mediated by the phosphodiesterase‑4 pathway.

- Psoriasis: reduces plaque formation, scaling and erythema in moderate to severe disease. - Psoriatic arthritis: alleviates joint pain, swelling and improves physical function. - Moderate to severe disease: offers an oral systemic therapy alternative to injectable biologics.

Apremilast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Headache: mild tension‑type headaches. - Upper respiratory tract infection: cold‑like symptoms. - Weight loss: gradual decrease in body weight. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Depression or suicidal thoughts: mood changes requiring immediate evaluation. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pancreatitis: abdominal pain with elevated enzymes. - Significant liver enzyme elevation: hepatitis risk. - Severe infections: opportunistic bacterial or fungal infections. - Cardiovascular events: rare cases of arrhythmia.

When prescribing Apremilast, clinicians should consider several safety precautions to minimize risk. - Pregnancy: safety not established; avoid unless potential benefit justifies risk. - Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. - Renal impairment: assess kidney function; dose adjustment may be required. - Hepatic impairment: monitor liver enzymes regularly. - Concomitant antidepressants: observe for mood changes. - Store at ambient temperature: keep below 25 °C, retain original packaging and protect from moisture.

Apremilast can interact with other medicines; some combinations should be avoided while others need careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce apremilast exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase apremilast levels and toxicity risk. - Anticoagulants (e.g., warfarin): potential for enhanced bleeding tendency.

Moderate Interactions (Monitor Closely): - Methotrexate: may increase hepatic toxicity; monitor liver function. - NSAIDs: additive gastrointestinal irritation. - Alcohol: may exacerbate liver enzyme elevations.